Zoltan Szucs1, James Joseph1,2,3, Tim J Larkin1, Bangwen Xie1, Sarah E Bohndiek1,2, Kevin M Brindle4,5, André A Neves6. 1. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. 2. Department of Physics, University of Cambridge, Cambridge, UK. 3. Present address: University of Dundee, School of Science and Engineering, Dundee, UK. 4. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. kmb1001@cam.ac.uk. 5. Department of Biochemistry, University of Cambridge, Cambridge, UK. kmb1001@cam.ac.uk. 6. Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. andre.neves@cruk.cam.ac.uk.
Abstract
BACKGROUND: Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of DCIS, and non-invasive detection of its presence and spatial extent could provide information not obtainable by biopsy. We describe here imaging of the distribution and extent of comedo-type necrosis in a model of human DCIS using C2Am, an imaging agent that binds to the phosphatidylserine exposed by necrotic cells. METHODS: We used an established xenograft model of human DCIS that mimics the histopathological features of the disease. Planar near-infrared and optoacoustic imaging, using fluorescently labeled C2Am, were used to image non-invasively the presence and extent of lesion necrosis. RESULTS: C2Am showed specific and sensitive binding to necrotic areas in DCIS tissue, detectable both in vivo and ex vivo. The imaging signal generated in vivo using near-infrared (NIR) fluorescence imaging was up to 6-fold higher in DCIS lesions than in surrounding fat pad or skin tissue. There was a correlation between the C2Am NIR fluorescence (Pearson R = 0.783, P = 0.0125) and optoacoustic signals (R > 0.875, P < 0.022) in the DCIS lesions in vivo and the corresponding levels of cell death detected histologically. CONCLUSIONS: C2Am is a targeted multi-modal imaging agent that could complement current anatomical imaging methods for detecting DCIS. Imaging the presence and spatial extent of necrosis may give better prognostic information than that obtained by biopsy alone.
BACKGROUND: Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of DCIS, and non-invasive detection of its presence and spatial extent could provide information not obtainable by biopsy. We describe here imaging of the distribution and extent of comedo-type necrosis in a model of human DCIS using C2Am, an imaging agent that binds to the phosphatidylserine exposed by necrotic cells. METHODS: We used an established xenograft model of human DCIS that mimics the histopathological features of the disease. Planar near-infrared and optoacoustic imaging, using fluorescently labeled C2Am, were used to image non-invasively the presence and extent of lesion necrosis. RESULTS: C2Am showed specific and sensitive binding to necrotic areas in DCIS tissue, detectable both in vivo and ex vivo. The imaging signal generated in vivo using near-infrared (NIR) fluorescence imaging was up to 6-fold higher in DCIS lesions than in surrounding fat pad or skin tissue. There was a correlation between the C2Am NIR fluorescence (Pearson R = 0.783, P = 0.0125) and optoacoustic signals (R > 0.875, P < 0.022) in the DCIS lesions in vivo and the corresponding levels of cell death detected histologically. CONCLUSIONS: C2Am is a targeted multi-modal imaging agent that could complement current anatomical imaging methods for detecting DCIS. Imaging the presence and spatial extent of necrosis may give better prognostic information than that obtained by biopsy alone.
Entities:
Keywords:
DCIS; Early detection; Multi-modal imaging; Necrosis; Optoacoustic
Authors: Béatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Lamia Benbrahim-Tallaa; Véronique Bouvard; Franca Bianchini; Kurt Straif Journal: N Engl J Med Date: 2015-06-03 Impact factor: 91.245
Authors: Beth T Harrison; E Shelley Hwang; Ann H Partridge; Alastair M Thompson; Stuart J Schnitt Journal: Mod Pathol Date: 2019-04-12 Impact factor: 7.842
Authors: Lars J Grimm; Marc D Ryser; Ann H Partridge; Alastair M Thompson; Jeremy S Thomas; Jelle Wesseling; E Shelley Hwang Journal: Ann Surg Oncol Date: 2017-08-09 Impact factor: 5.344
Authors: S E Pinder; C Duggan; I O Ellis; J Cuzick; J F Forbes; H Bishop; I S Fentiman; W D George Journal: Br J Cancer Date: 2010-06-01 Impact factor: 7.640
Authors: Jeremy Thomas; Andrew Hanby; Sarah E Pinder; Graham Ball; Gill Lawrence; Anthony Maxwell; Matthew Wallis; Andrew Evans; Hilary Dobson; Karen Clements; Alastair Thompson Journal: Eur J Cancer Date: 2014-05-26 Impact factor: 9.162
Authors: Gurdeep S Mannu; Emma J Groen; Zhe Wang; Michael Schaapveld; Esther H Lips; Monica Chung; Ires Joore; Flora E van Leeuwen; Hendrik J Teertstra; Gonneke A O Winter-Warnars; Sarah C Darby; Jelle Wesseling Journal: Breast Cancer Res Treat Date: 2019-08-06 Impact factor: 4.872
Authors: Zoltan Szucs; James Joseph; Tim J Larkin; Bangwen Xie; Sarah E Bohndiek; Kevin M Brindle; André A Neves Journal: Breast Cancer Res Date: 2021-03-15 Impact factor: 6.466